RTX Q2 Beat Reinforces Recovery Narrative, But Valuation Leaves Little Room for Error

What happened

RTX Corp delivered a strong Q2 2026 with adjusted EPS 14% above consensus on 11.9% sales growth, reinforcing that commercial aftermarket strength and defense demand are materializing. However, the company's filings still show Pratt PW1100 AOG levels elevated through 2026, a $0.5B compensation accrual, and tariff overhang, meaning the headline beat masks ongoing operational drags. The market initially cheered the results as evidence of normalization, but at 36x P/E and 19.7x EV/EBITDA, the stock already discounts a smooth recovery. The DeepValue report's thesis hinges on concrete proof: Pratt shipments above 235 quarterly, Airbus no longer citing Pratt as bottleneck, and broader missile awards beyond Patriot. This quarter moves the needle slightly but does not fully close the gap; investors need at least one more clean quarter to confirm the trajectory.

Implication

The Q2 results are a positive data point that reduces downside risk, but the stock's premium valuation and lingering uncertainties around Pratt and defense conversion mean investors should not chase. A better entry exists below $175 or after sustained Pratt shipment improvement and missile award announcements.

Thesis delta

The Q2 beat modestly de-risks the near-term earnings trajectory, but the core thesis remains unchanged: RTX's valuation already prices in a smooth Pratt recovery and defense conversion. The evidence from Q2 does not yet fully confirm either, so the wait-and-see stance persists until the next quarter shows Pratt shipments rising and missile awards converting.